OcuMension Therapeutics lists on HKEx
Ophthalmic therapy provider OcuMension Therapeutics goes public in Hong Kong. Eight Roads Ventures China invested in its Series B round.

Opthalmic therapy provider OcuMension Therapeutics offered 105.93 million shares at a price of HK$14.66, raising HK$1.55 billion. The stock rose as much as 193 per cent to HK$43 in early trading.

It was oversubscribed 1,895.76 times. The funds will mainly be used to develop its new drugs as well as its core product OT-401, which treats chronic eye inflammation affecting the posterior segment of the eye.